source
- Neurosterix raises $105 million Series B to advance schizophrenia candidateNeurosterix announced it has closed a $105 million Series B financing round. The capital will be used to develop its lead drug candidate for schizophrenia, which targets a pathway also addressed by…
- FDA issues warning letters to two Chinese API makers for refusing record requestsThe U.S. Food and Drug Administration sent warning letters to Chongqing Qiancan Technology and Tianjin Healthcare Medical Technology after both companies declined to provide records the agency requ…